Skip to main content
. 2023 Jun 1;14:1193791. doi: 10.3389/fphar.2023.1193791

FIGURE 1.

FIGURE 1

Experimental overview. One PDAC PDX displays notable sensibility to gemcitabine. (A) Schematic diagram of experiments. PDXs of PDAC patient tumors were established and propagated by xenograft transplantation in NOD mice for gemcitabine screening. PDXs most sensitive to gemcitabine were screened (PC-12) to perform single-cell RNA-seq. (B) Relative tumor growth rate (T/C%) of 17 PDAC PDX models treated with gemcitabine (n = 5–8) versus untreated (n = 5–8). (C) PC-12 xenografts from NOD mice were treated intraperitoneally with normal saline control or gemcitabine at 100 mg/kg twice per week for 4 weeks. Each group contained six mice. Tumor volume and weight were then measured. (D) Growth curve of PC-12 PDX tumors treated with gemcitabine or untreated (n = 6; p < 0.001). (E) Tissue processing pipeline for single-cell RNA-seq and bulk RNA-seq. (F) Representative H&E sections of the PDX in the control group and gem group.